Endogenous synthesis of n-3 polyunsaturated fatty acids in Fat-1 mice is associated with increased mammary gland and liver Syndecan-1

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Sun, Haiguo ^a   Hu, Yunping ^a   Gu, Zhennan ^a   Wilson, Martha D ^a   Chen, Yong Q ^a   Rudel, Lawrence L ^a   Willingham, Mark C ^a   Edwards, Iris J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; SYNDECAN 1; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; ACYL COENZYME A DESATURASE; CAENORHABDITIS ELEGANS PROTEIN; CHOLESTEROL; FAT 1 PROTEIN, C ELEGANS; FAT-1 PROTEIN, C ELEGANS; PHOSPHOLIPID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FAT INTAKE; FATTY ACID ANALYSIS; FATTY ACID SYNTHESIS; FEMALE; IN VIVO STUDY; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; LIVER; MAMMARY GLAND; MOUSE; NONHUMAN; UPREGULATION; ANIMAL; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; UDDER; WESTERN BLOTTING;

ANIMALIA; MUS;

ANIMALS; BLOTTING, WESTERN; CAENORHABDITIS ELEGANS PROTEINS; CHOLESTEROL; FATTY ACID DESATURASES; FATTY ACIDS, OMEGA-3; FEMALE; IMMUNOHISTOCHEMISTRY; LIVER; MAMMARY GLANDS, ANIMAL; MICE; MICE, TRANSGENIC; PHOSPHOLIPIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SYNDECAN-1; TRIGLYCERIDES;

EID: 79957794695     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020502     Document Type: Article

References (71)

1. Sasaki S, Horacsek M, Kesteloot H, (1993) An ecological study of the relationship between dietary fat intake and breast cancer mortality. Prev Med 22: 187-202.
2. Kaizer L, Boyd NF, Kriukov V, Tritchler D, (1989) Fish consumption and breast cancer risk: an ecological study. Nutr Cancer 12: 61-68.
3. Hursting SD, Thornquist M, Henderson MM, (1990) Types of dietary fat and the incidence of cancer at five sites. Prev Med 19: 242-253.
4. Reddy BS, Cohen LA, McCoy GD, Hill P, Weisburger JH, et al. (1980) Nutrition and its relationship to cancer. Adv Cancer Res 32: 237-345.
5. Braden LM, Carroll KK, (1986) Dietary polyunsaturated fat in relation to mammary carcinogenesis in rats. Lipids 21: 285-288.
6. Abou-el-Ela SH, Prasse KW, Carroll R, Wade AE, Dharwadkar S, et al. (1988) Eicosanoid synthesis in 7,12-dimethylbenz(a)anthracene-induced mammary carcinomas in Sprague-Dawley rats fed primrose oil, menhaden oil or corn oil diet. Lipids 23: 948-954.
7. Abou-el-Ela SH, Prasse KW, Farrell RL, Carroll RW, Wade AE, et al. (1989) Effects of D,L-2-difluoromethylornithine and indomethacin on mammary tumor promotion in rats fed high n-3 and/or n-6 fat diets. Cancer Res 49: 1434-1440.
8. Jurkowski JJ, Cave WT Jr, (1985) Dietary effects of menhaden oil on the growth and membrane lipid composition of rat mammary tumors. J Natl Cancer Inst 74: 1145-1150.
9. Rose DP, Connolly JM, (1993) Effects of dietary omega-3 fatty acids on human breast cancer growth and metastases in nude mice. J Natl Cancer Inst 85: 1743-1747.
10. Rose DP, Hatala MA, Connolly JM, Rayburn J, (1993) Effect of diets containing different levels of linoleic acid on human breast cancer growth and lung metastasis in nude mice. Cancer Res 53: 4686-4690.
11. Rose DP, Connolly JM, Rayburn J, Coleman M, (1995) Influence of diets containing eicosapentaenoic or docosahexaenoic acid on growth and metastasis of breast cancer cells in nude mice. J Natl Cancer Inst 87: 587-592.
12. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P, (1988) Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54: 105-115.
13. Yee LD, Young DC, Rosol TJ, Vanbuskirk AM, Clinton SK, (2005) Dietary (n-3) polyunsaturated fatty acids inhibit HER-2/neu-induced breast cancer in mice independently of the PPARgamma ligand rosiglitazone. J Nutr 135: 983-988.
14. Berquin IM, Edwards IJ, Chen YQ, (2008) Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Lett 269: 363-377.
15. Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A, (2004) Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 79: 935-945.
16. Noguchi M, Earashi M, Minami M, Kinoshita K, Miyazaki I, (1995) Effects of eicosapentaenoic and docosahexaenoic acid on cell growth and prostaglandin E and leukotriene B production by a human breast cancer cell line (MDA-MB-231). Oncology 52: 458-464.
17. Shikano M, Masuzawa Y, Yazawa K, Takayama K, Kudo I, et al. (1994) Complete discrimination of docosahexaenoate from arachidonate by 85 kDa cytosolic phospholipase A2 during the hydrolysis of diacyl- and alkenylacylglycerophosphoethanolamine. Biochim Biophys Acta 1212: 211-216.
18. Simopoulos AP, (2008) The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med (Maywood) 233: 674-688.
19. Rose DP, Connolly JM, (1999) Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 83: 217-244.
20. Edwards IJ, Berquin IM, Sun H, O'Flaherty J T, Daniel LW, et al. (2004) Differential effects of delivery of omega-3 fatty acids to human cancer cells by low-density lipoproteins versus albumin. Clin Cancer Res 10: 8275-8283.
21. Sun H, Berquin IM, Edwards IJ, (2005) Omega-3 polyunsaturated fatty acids regulate syndecan-1 expression in human breast cancer cells. Cancer Res 65: 4442-4447.
22. Sun H, Berquin IM, Owens RT, O'Flaherty JT, Edwards IJ, (2008) Peroxisome proliferator-activated receptor gamma-mediated up-regulation of syndecan-1 by n-3 fatty acids promotes apoptosis of human breast cancer cells. Cancer Res 68: 2912-2919.
23. Liu W, Litwack ED, Stanley MJ, Langford JK, Lander AD, et al. (1998) Heparan sulfate proteoglycans as adhesive and anti-invasive molecules. Syndecans and glypican have distinct functions. J Biol Chem 273: 22825-22832.
24. Langford JK, Yang Y, Kieber-Emmons T, Sanderson RD, (2005) Identification of an invasion regulatory domain within the core protein of syndecan-1. J Biol Chem 280: 3467-3473.
25. Beauvais DM, Rapraeger AC, (2004) Syndecans in tumor cell adhesion and signaling. Reprod Biol Endocrinol 2: 3.
26. Vuoriluoto K, Jokinen J, Kallio K, Salmivirta M, Heino J, et al. (2008) Syndecan-1 supports integrin alpha2beta1-mediated adhesion to collagen. Exp Cell Res 314: 3369-3381.
27. Ruoslahti E, (1989) Proteoglycans in cell regulation. J Biol Chem 264: 13369-13372.
28. Ruoslahti E, Yamaguchi Y, (1991) Proteoglycans as modulators of growth factor activities. Cell 64: 867-869.
29. Bernfield M, Kokenyesi R, Kato M, Hinkes MT, Spring J, et al. (1992) Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol 8: 365-393.
30. Liebersbach BF, Sanderson RD, (1994) Expression of syndecan-1 inhibits cell invasion into type I collagen. J Biol Chem 269: 20013-20019.
31. Ishikawa T, Kramer RH Sdc1 negatively modulates carcinoma cell motility and invasion. Exp Cell Res 316: 951-965.
32. Dhodapkar MV, Abe E, Theus A, Lacy M, Langford JK, et al. (1998) Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood 91: 2679-2688.
33. Kang JX, Wang J, Wu L, Kang ZB, (2004) Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. Nature 427: 504.
34. Berquin IM, Min Y, Wu R, Wu J, Perry D, et al. (2007) Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest 117: 1866-1875.
35. Carr TP, Andresen CJ, Rudel LL, (1993) Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts. Clin Biochem 26: 39-42.
36. Rouser G, Fkeischer S, Yamamoto A, (1970) Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 5: 494-496.
37. Hu Y, Sun H, Owens RT, Wu J, Chen YQ, et al. (2009) Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia 11: 1042-1053.
38. Stanford KI, Bishop JR, Foley EM, Gonzales JC, Niesman IR, et al. (2009) Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J Clin Invest 119: 3236-3245.
39. Liu YE, Pu W, Wang J, Kang JX, Shi YE, (2007) Activation of Stat5 and induction of a pregnancy-like mammary gland differentiation by eicosapentaenoic and docosapentaenoic omega-3 fatty acids. FEBS J 274: 3351-3362.
40. Edwards IJ, Sun H, Hu Y, Berquin IM, O'Flaherty JT, et al. (2008) In vivo and in vitro regulation of syndecan 1 in prostate cells by N-3 polyunsaturated fatty acids. J Biol Chem 283: 18441-18449.
41. Ma DW, Ngo V, Huot PS, Kang JX, (2006) N-3 polyunsaturated fatty acids endogenously synthesized in fat-1 mice are enriched in the mammary gland. Lipids 41: 35-39.
42. Orr SK, Tong JY, Kang JX, Ma DW, Bazinet RP. The fat-1 mouse has brain docosahexaenoic acid levels achievable through fish oil feeding. Neurochem Res 35: 811-819.
43. Nowak J, Weylandt KH, Habbel P, Wang J, Dignass A, et al. (2007) Colitis-associated colon tumorigenesis is suppressed in transgenic mice rich in endogenous n-3 fatty acids. Carcinogenesis 28: 1991-1995.
44. Jia Q, Lupton JR, Smith R, Weeks BR, Callaway E, et al. (2008) Reduced colitis-associated colon cancer in Fat-1 (n-3 fatty acid desaturase) transgenic mice. Cancer Res 68: 3985-3991.
45. Xia S, Lu Y, Wang J, He C, Hong S, et al. (2006) Melanoma growth is reduced in fat-1 transgenic mice: impact of omega-6/omega-3 essential fatty acids. Proc Natl Acad Sci U S A 103: 12499-12504.
46. Lu Y, Nie D, Witt WT, Chen Q, Shen M, et al. (2008) Expression of the fat-1 gene diminishes prostate cancer growth in vivo through enhancing apoptosis and inhibiting GSK-3 beta phosphorylation. Mol Cancer Ther 7: 3203-3211.
47. Xia SH, Wang J, Kang JX, (2005) Decreased n-6/n-3 fatty acid ratio reduces the invasive potential of human lung cancer cells by downregulation of cell adhesion/invasion-related genes. Carcinogenesis 26: 779-784.
48. Hu Y, Sun H, Owens RT, Gu Z, Wu J,et al. Syndecan-1-dependent suppression of PDK1/Akt/bad signaling by docosahexaenoic acid induces apoptosis in prostate cancer. Neoplasia 12: 826-836.
49. MacLean CH, Newberry SJ, Mojica WA, Khanna P, Issa AM, et al. (2006) Effects of omega-3 fatty acids on cancer risk: a systematic review. Jama 295: 403-415.
50. Chen YQ, Berquin IM, Daniel LW, Edwards IJ, O'Flaherty JT, et al. (2006) Omega-3 fatty acids and cancer risk. Jama 296: 282; author reply 282.
51. Bougnoux P, Hajjaji N, Ferrasson MN, Giraudeau B, Couet C, et al. (2009) Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Br J Cancer 101: 1978-1985.
52. Bougnoux P, Hajjaji N, Maheo K, Couet C, Chevalier S Fatty acids and breast cancer: sensitization to treatments and prevention of metastatic re-growth. Prog Lipid Res 49: 76-86.
53. Mikami S, Ohashi K, Usui Y, Nemoto T, Katsube K, et al. (2001) Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas. Jpn J Cancer Res 92: 1062-1073.
54. Anttonen A, Kajanti M, Heikkila P, Jalkanen M, Joensuu H, (1999) Syndecan-1 expression has prognostic significance in head and neck carcinoma. Br J Cancer 79: 558-564.
55. Nackaerts K, Verbeken E, Deneffe G, Vanderschueren B, Demedts M, et al. (1997) Heparan sulfate proteoglycan expression in human lung-cancer cells. Int J Cancer 74: 335-345.
56. Pulkkinen JO, Penttinen M, Jalkanen M, Klemi P, Grenman R, (1997) Syndecan-1: a new prognostic marker in laryngeal cancer. Acta Otolaryngol 117: 312-315.
57. Matsumoto A, Ono M, Fujimoto Y, Gallo RL, Bernfield M, et al. (1997) Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int J Cancer 74: 482-491.
58. Kumar-Singh S, Jacobs W, Dhaene K, Weyn B, Bogers J, et al. (1998) Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome. J Pathol 186: 300-305.
59. Inki P, Joensuu H, Grenman R, Klemi P, Jalkanen M, (1994) Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. Br J Cancer 70: 319-323.
60. Fujiya M, Watari J, Ashida T, Honda M, Tanabe H, et al. (2001) Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer. Jpn J Cancer Res 92: 1074-1081.
61. Stanley MJ, Stanley MW, Sanderson RD, Zera R, (1999) Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am J Clin Pathol 112: 377-383.
62. Loussouarn D, Campion L, Sagan C, Frenel JS, Dravet F, et al. (2008) Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas. Br J Cancer 98: 1993-1998.
63. Davies EJ, Blackhall FH, Shanks JH, David G, McGown AT, et al. (2004) Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res 10: 5178-5186.
64. Wiksten JP, Lundin J, Nordling S, Lundin M, Kokkola A, et al. (2001) Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer 95: 1-6.
65. Fitzgerald ML, Wang Z, Park PW, Murphy G, Bernfield M, (2000) Shedding of syndecan-1 and-4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 148: 811-824.
66. Wang Z, Gotte M, Bernfield M, Reizes O, (2005) Constitutive and accelerated shedding of murine syndecan-1 is mediated by cleavage of its core protein at a specific juxtamembrane site. Biochemistry 44: 12355-12361.
67. Mali M, Andtfolk H, Miettinen HM, Jalkanen M, (1994) Suppression of tumor cell growth by syndecan-1 ectodomain. J Biol Chem 269: 27795-27798.
68. Nikolova V, Koo CY, Ibrahim SA, Wang Z, Spillmann D, et al. (2009) Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis 30: 397-407.
69. Kato M, Wang H, Kainulainen V, Fitzgerald ML, Ledbetter S, et al. (1998) Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med 4: 691-697.
70. Ilan N, Elkin M, Vlodavsky I, (2006) Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 38: 2018-2039.
71. Sanderson RD, Yang Y, Kelly T, MacLeod V, Dai Y, et al. (2005) Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies. J Cell Biochem 96: 897-905.